New LaunchJul 7, 2026, 09:14 AM
Alamar Biosciences Launches First Commercial eMTBR-Tau Immunoassay
AI Summary
Alamar Biosciences, Inc. announced the launch of its first commercial eMTBR-Tau immunoassay, a significant development for Alzheimer's disease research and diagnosis. This new assay, available in NULISAseq™ Neuro 220 multiplexed panel kits and as a single-plex assay, measures a plasma biomarker that specifically reflects tau tangle pathology, a core component of Alzheimer's progression. The NULISA platform enables highly sensitive and specific measurement, offering a non-invasive, blood-based alternative to traditional tau PET imaging. The company will present data on the assay's performance and clinical findings at the Alzheimer’s Association International Conference (AAIC) 2026.
Key Highlights
- Alamar Biosciences launched the first commercial eMTBR-Tau immunoassay.
- The immunoassay is available in NULISAseq™ Neuro 220 multiplexed panel kits.
- It is immediately deployable on the entire installed base of ARGO™ HT instruments.
- The assay is also available as a single-plex assay through the Technology Access Program (TAP).
- It measures eMTBR-Tau, a plasma biomarker for tau tangle pathology in Alzheimer's disease.
- The NULISA platform delivers attomolar sensitivity and multiplexing for the assay.
- Data on eMTBR-Tau will be featured at Alamar's workshop at AAIC 2026 on July 14.
Price Impact
More from ALMR